Cytology and Biomarkers in NMIBC
Cystoscopy and cytology remain the standard for diagnosis, but a plethora of urinary biomarkers could someday be a useful adjunct to NMIBC surveillance.
Bladder Cancer
FEATURES
Latest Bladder Cancer News
Complete TURBT Before Neoadjuvant Chemotherapy Improves MIBC Outcomes
Complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy in patients scheduled to undergo radical cystectomy for muscle-invasive bladder is associated with improved overall and cancer-specific survival, a study found.
Trodelvy Gets Accelerated Approval for Urothelial Cancer
The accelerated approval was based on data from the multicenter, open-label, phase 2 TROPHY study.
Prophylactic Ureteral Stenting Linked to Upper Tract Urothelial Carcinoma
In current urological practice, clinicians decide whether to place a ureteral stent or nephrostomy, but evidence-based treatment guidance is needed.
FDA Investigating Infections Tied to Reprocessing Urological Endoscopes
More than 450 medical device reports of patient infections, potential contamination recorded from Jan. 1, 2017, to Feb. 20, 2021
Seminal Vesicle-Sparing in Radical Cystectomy Shown to Improve Outcomes
Seminal vesicle-sparing radical cystectomy improved functional results over a median of 64 months without compromising oncologic outcomes, according to investigators.
Oncologic Outcomes, Costs of High-Risk NMIBC Need to Improve
High-risk NMIBC progression more than doubled healthcare costs over 5 years compared with no progression, a study found.
Indications Withdrawn as FDA Evaluates Several Accelerated Approvals
To prove clinical benefit, the FDA requires manufacturers to conduct confirmatory trials, also known as a phase 4 studies.
Tecentriq Indication for Prior-Platinum Treated Bladder Cancer Withdrawn
In 2016, the FDA granted accelerated approval to Tecentriq for prior-platinum treated metastatic urothelial carcinoma based on tumor response rate and duration of response.
Bladder Pressure May Influence Intravesical Drug Delivery
Using porcine bladders, researchers investigated whether bladder pressure affects the extent to which gemcitabine penetrates the bladder wall with this treatment modality.
Primary EV-301 Results Confirm Enfortumab Vedotin’s Superiority Over Chemotherapy in Advanced Urothelial Carcinoma
Powles et al present the primary results from the phase 3 EV-301 trial in advanced urothelial carcinoma.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Bladder Cancer
Loading... 
Loading...